Anti-malarial Drugs Market, by Drug Class (Aminoquinolines, Quinoline-methanol (4-quinolinemethanols), Cinchona Alkaloids, Biguanides, Sulfonamides and Sulfones, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospi

Anti-malarial Drugs Market, by Drug Class (Aminoquinolines, Quinoline-methanol (4-quinolinemethanols), Cinchona Alkaloids, Biguanides, Sulfonamides and Sulfones, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Malaria is common infectious disease caused by the protozoan parasite, Plasmodium parasites. The bite of an infected female Anopheles mosquito transmits a parasite to the person’s body, which then enters into the person’s liver where the production of parasite occurs. Human malaria are generally caused by five types of plasmodium parasites, including P. falciparum, P. malariae, P. ovale, P. vivax, and P.knowlesi. Among these, P. falciparum and P. vivax are the most dangerous species of parasite causing highest number of malaria mortality. Early diagnosis and efficient treatment are crucial measures to control malaria. Different types of drugs such as quinine, chloroquine, mefloquine, proguanil, primaquine, and others are used in the treatment of malaria. Moreover, some combination drugs such as Pyrimethamine & sulfadoxine, Artemether & lumefantrine, and others are also prescribed for treating the disease. According to the World Health Organization (WHO), around 91 countries and territories are at the risk of malaria transmission.
Market Dynamics
Malaria is considered as a life-threatening disease affecting large number of population across the world. According to the World Health Organization (WHO), in 2021, around 228 million estimated cases of malaria were diagnosed, globally. Moreover, global death toll due to malaria reached 405,000 in 2021 and an estimated 219 million cases were diagnosed in 2017. Sub-Saharan Africa is the most affected region due to malaria and according to WHO estimation, the region accounted for 93% of malaria cases among all the global cases. Thus, the increasing incidence of malaria in the world is expected to drive growth of the anti-malaria drugs market during the forecast period.
Moreover, various pharmaceutical companies are actively participating in research and development activities, in order to develop novel drug entity for treatment of malaria. For instance, in November 2017, Novartis Pharmaceuticals initiated phase 2 clinical trial to study the safety of the maximum dose of the investigational drug KAE609 in adult patients with uncomplicated malaria. The study is estimated to be completed in April 30, 2022. Such, increasing number of lead candidates is expected to contribute to growth of the global anti-malaria drugs market in the near future.
Key features of the study:
This report provides in-depth analysis of the global anti-malarial drugs market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrixes for this market
This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles leading players in the global anti-malarial drugs market based on the following parameters – company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA, Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care, Bayer AG, and Roche Inc
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, governmental initiatives, technological up-gradation, market expansions, and marketing tactics
The global anti-malarial drugs market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the global anti-malarial drugs industry, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Anti-malarial Drugs Market, By Drug Class:
Aminoquinolines
Quinoline-methanol (4-quinolinemethanols)
Cinchona Alkaloids
Biguanides
Sulfonamides and sulfones
Others
Global Anti-malarial Drugs Market, By Route of Administration:
Oral
Injectable
Global Anti-malarial Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Anti-malarial Drugs Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Class:
Aminoquinolines
Quinoline-methanol (4-quinolinemethanols)
Cinchona Alkaloids
Biguanides
Sulfonamides and sulfones
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class:
Aminoquinolines
Quinoline-methanol (4-quinolinemethanols)
Cinchona Alkaloids
Biguanides
Sulfonamides and sulfones
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class:
Aminoquinolines
Quinoline-methanol (4-quinolinemethanols)
Cinchona Alkaloids
Biguanides
Sulfonamides and sulfones
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class:
Aminoquinolines
Quinoline-methanol (4-quinolinemethanols)
Cinchona Alkaloids
Biguanides
Sulfonamides and sulfones
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Class:
Aminoquinolines
Quinoline-methanol (4-quinolinemethanols)
Cinchona Alkaloids
Biguanides
Sulfonamides and sulfones
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Class:
Aminoquinolines
Quinoline-methanol (4-quinolinemethanols)
Cinchona Alkaloids
Biguanides
Sulfonamides and sulfones
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Ipca Laboratories Ltd.,*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Zydus Cadila
Merck KGaA
Pfizer
GlaxoSmithKline Plc.
Cipla Ltd
Ranbaxy Laboratories
Novartis AG
Alvizia Health Care
Bayer AG
Roche Inc.
“*” marked represents similar segmentation in other categories in the respective section